Cervical cancer therapies: Current challenges and future perspectives
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cervical cancer therapies: Current challenges and future perspectives
Authors
Keywords
Cervical cancer, HPV E6/E7 oncoproteins, Targeted therapy, HPV therapeutic Vaccines, Immune checkpoint inhibitors, Combination therapy
Journal
Tumour Virus Research
Volume 13, Issue -, Pages 200238
Publisher
Elsevier BV
Online
2022-04-21
DOI
10.1016/j.tvr.2022.200238
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunotherapy in Cervical Cancer
- (2021) Dennis Mauricio et al. Current Oncology Reports
- Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
- (2021) Simona Duranti et al. Cancers
- Radiation therapy‐associated toxicity: Etiology, management, and prevention
- (2021) Kyle Wang et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
- (2021) David M. O'Malley et al. GYNECOLOGIC ONCOLOGY
- Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
- (2020) Asmita Pal et al. Frontiers in Microbiology
- Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy
- (2020) Shahin Aghamiri et al. Expert Opinion on Drug Delivery
- Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions
- (2020) Masahiro Kagabu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The efficacy and safety of pembrolizumab in advanced cervical cancer—A real world treatment study in an irish healthcare setting.
- (2020) Iseult Browne et al. JOURNAL OF CLINICAL ONCOLOGY
- Recent Advances in CRISPR/Cas9 Delivery Strategies
- (2020) Bon Ham Yip Biomolecules
- A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
- (2020) Andrea Ghelli Luserna di Rorà et al. Journal of Hematology & Oncology
- Cervical cancer
- (2019) Paul A Cohen et al. LANCET
- Cervical Cancer: An Overview of Pathophysiology and Management
- (2019) Cynae A. Johnson et al. Seminars in Oncology Nursing
- Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
- (2019) Amir A. Jazaeri et al. JOURNAL OF CLINICAL ONCOLOGY
- Key Molecular Events in Cervical Cancer Development
- (2019) Shandra Devi Balasubramaniam et al. Medicina-Lithuania
- LBA62Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
- (2019) R W Naumann et al. ANNALS OF ONCOLOGY
- PARP Inhibition in Cancer: An Update on Clinical Development
- (2019) Esha Sachdev et al. Targeted Oncology
- Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
- (2019) Marc Arbyn et al. Lancet Global Health
- Chemotherapy and targeted therapy in the management of cervical cancer
- (2018) Lalit Kumar et al. CURRENT PROBLEMS IN CANCER
- HPV: Molecular pathways and targets
- (2018) Shilpi Gupta et al. CURRENT PROBLEMS IN CANCER
- Temporal trends in the epidemiology of cervical cancer in South Africa (1994-2012)
- (2018) Gbenga Olorunfemi et al. INTERNATIONAL JOURNAL OF CANCER
- A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
- (2018) Partha Basu et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis
- (2018) Nicole Yeo-Teh et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16�E6/E7
- (2018) Naoto Sato et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma
- (2018) Stephanie Lheureux et al. JAMA Oncology
- Cancer of the cervix uteri
- (2018) Neerja Bhatla et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
- (2018) Pedro T. Ramirez et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
- (2017) Leisha A. Emens et al. EUROPEAN JOURNAL OF CANCER
- Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
- (2017) Jean-Sebastien Frenel et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
- (2017) Krishnansu S Tewari et al. LANCET
- Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer
- (2017) Emeka K Enwere et al. MODERN PATHOLOGY
- Biomarkers of resistance to radiation therapy: a prospective study in cervical carcinoma
- (2017) P. Moreno-Acosta et al. Radiation Oncology
- Targeting Persistent Human Papillomavirus Infection
- (2017) et al. Viruses-Basel
- The role of integration in oncogenic progression of HPV-associated cancers
- (2017) Alison A. McBride et al. PLoS Pathogens
- The ratio of serum Angiopoietin-1 to Angiopoietin-2 in patients with cervical cancer is a valuable diagnostic and prognostic biomarker
- (2017) Ping Yang et al. PeerJ
- A Phase I Trial of Paclitaxel, Cisplatin and Veliparib in the Treatment of Persistent or Recurrent Carcinoma of the Cervix: An NRG Oncology Study (NCT#01281852)
- (2016) P.H. Thaker et al. ANNALS OF ONCOLOGY
- Chemotherapy and molecular targeting therapy for recurrent cervical cancer
- (2016) Naotake Tsuda et al. Chinese Journal of Cancer Research
- Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis
- (2016) Ioannis C. Kotsopoulos et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Targeting WEE1 Kinase in Cancer
- (2016) Christopher J. Matheson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Molecular mechanisms of cisplatin resistance in cervical cancer
- (2016) Xueqiong Zhu et al. Drug Design Development and Therapy
- Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis
- (2016) Wei-Jie Tian et al. PLoS One
- Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline
- (2015) H. Hirte et al. Current Oncology
- A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix
- (2015) Charles Kunos et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Cancer of the cervix uteri
- (2015) Adriana Bermudez et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
- (2015) Sanja Stevanović et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
- (2015) Cornelia L Trimble et al. LANCET
- Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240)
- (2015) Richard T Penson et al. LANCET ONCOLOGY
- Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
- (2015) Louisa Mezache et al. MODERN PATHOLOGY
- Tumor-infiltrating lymphocytes for the treatment of metastatic cancer
- (2015) M.H. Geukes Foppen et al. Molecular Oncology
- In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9
- (2014) Shuai Zhen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Delays in diagnosis of young females with symptomatic cervical cancer in England: an interview-based study
- (2014) Anita W Lim et al. BRITISH JOURNAL OF GENERAL PRACTICE
- Development and Applications of CRISPR-Cas9 for Genome Engineering
- (2014) Patrick D. Hsu et al. CELL
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- (2014) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage
- (2014) Jung Wook Park et al. RADIOTHERAPY AND ONCOLOGY
- The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
- (2014) M. A. Lemmon et al. Cold Spring Harbor Perspectives in Biology
- Disruption of HPV16-E7 by CRISPR/Cas System Induces Apoptosis and Growth Inhibition in HPV16 Positive Human Cervical Cancer Cells
- (2014) Zheng Hu et al. Biomed Research International
- Emerging Biological Treatments for Uterine Cervical Carcinoma
- (2014) Patrizia Vici et al. Journal of Cancer
- Wee1 kinase as a target for cancer therapy
- (2013) Khanh Do et al. CELL CYCLE
- Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
- (2013) A.V. Tinker et al. GYNECOLOGIC ONCOLOGY
- Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa
- (2013) Lynette Denny et al. INTERNATIONAL JOURNAL OF CANCER
- Human papillomavirus and cervical cancer
- (2013) Emma J Crosbie et al. LANCET
- The Significance of Tumoral ERCC1 Status in Patients With Locally Advanced Cervical Cancer Treated With Chemoradiation Therapy: A Multicenter Clinicopathologic Analysis
- (2012) Corinne M. Doll et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Gynaecological symptoms reported by young women: examining the potential for earlier diagnosis of cervical cancer
- (2011) S. Stapley et al. FAMILY PRACTICE
- Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study
- (2011) John Farley et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
- (2011) Alessandro D. Santin et al. GYNECOLOGIC ONCOLOGY
- PARP inhibitors: its role in treatment of cancer
- (2011) Alice Chen Chinese Journal of Cancer
- A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix
- (2010) Russell J. Schilder et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- CD1d, a Sentinel Molecule Bridging Innate and Adaptive Immunity, Is Downregulated by the Human Papillomavirus (HPV) E5 Protein: a Possible Mechanism for Immune Evasion by HPV
- (2010) S. Miura et al. JOURNAL OF VIROLOGY
- Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study
- (2009) Jennifer R Moodley et al. BMC CANCER
- Human papillomavirus type 16 E5 protein inhibits hydrogen peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells
- (2009) J.-M. Oh et al. CARCINOGENESIS
- Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial
- (2009) J.E. Kurtz et al. GYNECOLOGIC ONCOLOGY
- All 4 di-leucine motifs in the first hydrophobic domain of the E5 oncoprotein of human papillomavirus type 16 are essential for surface MHC class I downregulation activity and E5 endomembrane localization
- (2009) Marc S. Cortese et al. INTERNATIONAL JOURNAL OF CANCER
- Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
- (2009) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
- Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials
- (2009) Janet E. Dancey et al. SEMINARS IN ONCOLOGY
- Papillomaviruses in the causation of human cancers — a brief historical account
- (2009) Harald zur Hausen VIROLOGY
- Poly(ADPR)polymerase inhibition and apoptosis induction in cDDP-treated human carcinoma cell lines
- (2008) Nadia Gambi et al. BIOCHEMICAL PHARMACOLOGY
- Type-Dependent Integration Frequency of Human Papillomavirus Genomes in Cervical Lesions
- (2008) S. Vinokurova et al. CANCER RESEARCH
- A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer
- (2007) A. Goncalves et al. GYNECOLOGIC ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now